- Home
- MCS vs MYGN Comparison
MCS vs MYGN Comparison
Compare MCS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCS
- MYGN
- Stock Information
- Founded
- MCS 1935
- MYGN 1991
- Country
- MCS United States
- MYGN United States
- Employees
- MCS N/A
- MYGN N/A
- Industry
- MCS Movies/Entertainment
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MCS Consumer Discretionary
- MYGN Health Care
- Exchange
- MCS Nasdaq
- MYGN Nasdaq
- Market Cap
- MCS 467.8M
- MYGN 423.1M
- IPO Year
- MCS N/A
- MYGN 1995
- Fundamental
- Price
- MCS $15.75
- MYGN $6.02
- Analyst Decision
- MCS Strong Buy
- MYGN Hold
- Analyst Count
- MCS 4
- MYGN 13
- Target Price
- MCS $24.75
- MYGN $13.50
- AVG Volume (30 Days)
- MCS 298.2K
- MYGN 2.4M
- Earning Date
- MCS 08-01-2025
- MYGN 08-05-2025
- Dividend Yield
- MCS 1.85%
- MYGN N/A
- EPS Growth
- MCS N/A
- MYGN N/A
- EPS
- MCS 0.47
- MYGN N/A
- Revenue
- MCS $734,999,000.00
- MYGN $832,900,000.00
- Revenue This Year
- MCS $12.99
- MYGN N/A
- Revenue Next Year
- MCS $4.39
- MYGN $6.64
- P/E Ratio
- MCS $32.34
- MYGN N/A
- Revenue Growth
- MCS 13.65
- MYGN 3.83
- 52 Week Low
- MCS $13.70
- MYGN $3.76
- 52 Week High
- MCS $23.16
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- MCS 50.00
- MYGN 62.34
- Support Level
- MCS $14.96
- MYGN $5.23
- Resistance Level
- MCS $15.36
- MYGN $6.07
- Average True Range (ATR)
- MCS 0.45
- MYGN 0.39
- MACD
- MCS 0.10
- MYGN 0.05
- Stochastic Oscillator
- MCS 95.29
- MYGN 81.27
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.